Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cellkine is an investigational allogeneic cell therapy developed by the Mayo Clinic for the treatment of chronic low back pain associated with lumbar facet joint arthropathy (LFJA). The therapy consists of culture-expanded mesenchymal stem cells (MSCs) derived from the bone marrow of healthy donors. These cells are administered via intra-articular injection directly into the affected lumbar facet joints. Cellkine is intended to address the underlying degenerative processes of LFJA through the immunomodulatory and trophic effects of the mesenchymal stem cells, which may reduce local inflammation and promote tissue stabilization. The product is manufactured at Mayo Clinic's cGMP facility in Florida and is currently being evaluated in Phase II clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cellkine.